Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136830

Published: 2020

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

Daniel Mertens, PhD, Christine Wolf, PhD, Carsten Maus, PhD, Michael Persicke, Katharina Filarsky, PhD, Hartmut Döhner, Peter Lichter, PhD, Thomas Höfer, PhD, Stephan Stilgenbauer, MD

Blood (2019) 134 (Supplement_1): 4275.

https://doi.org/10.1182/blood-2019-127837

Published: 2019

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

Towards Stratification of Lymphomas with Involvement of the Central Nervous System Using miRNA-Seq from Small Volumes of Cerebrospinal Fluid

Sarah Grasedieck, MSc, Medhanie A. Mulaw, Jun.-Prof. Dr., Christina Miller, Arefeh Rouhi, PhD, Jeanette K Doorduijn, MD PhD, Jacoline E. Bromberg, MD, Florian Kuchenbauer, Daniel Mertens, PhD

Blood (2016) 128 (22): 1751.

https://doi.org/10.1182/blood.V128.22.1751.1751

Published: 2016

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 2436.

https://doi.org/10.1182/blood.V126.23.2436.2436

Published: 2015

Journal Articles

Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Blood (2015) 126 (23): 362.

https://doi.org/10.1182/blood.V126.23.362.362

Published: 2015

Journal Articles

Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically

Irina Idler, PhD, Deyan Yosifov, PhD, Nupur Bhattacharya, PhD, Michaela Reichenzeller, PhD, Viola Meyer-Pannwitt, Daria Ezerina, Annika Scheffold, M.Sc., Sabrina Kugler, PhD, Tobias Dick, PhD, Hartmut Dohner, MD, Stephan Stilgenbauer, MD, Daniel Mertens, PhD

Blood (2015) 126 (23): 4140.

https://doi.org/10.1182/blood.V126.23.4140.4140

Published: 2015

Journal Articles

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Annika Scheffold, M.Sc., Billy Michael Chelliah Jebaraj, PhD, André Lechel, PhD, Sarah-Fee Katz, PhD, Daniela Steinbrecher, M.Sc., Vanni Torresi, M.Sc., Christof Schneider, MD, Daniel Mertens, PhD, Hartmut Döhner, MD, Karl-Lenhard Rudolph, MD, Stephan Stilgenbauer, MD

Blood (2015) 126 (23): 1724.

https://doi.org/10.1182/blood.V126.23.1724.1724

Published: 2015

Journal Articles

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Jennifer Edelmann, MD, Jenny Saub, Stefan Ibach, Karlheinz Holzmann, PhD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Daniel Mertens, PhD, Thorsten Zenz, MD, Florence Cymbalista, MD, Veronique Leblond, MD PhD, Alain Delmer, MD PhD, John G. Gribben, MD DSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3288.

https://doi.org/10.1182/blood.V124.21.3288.3288

Published: 2014

Journal Articles

Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911)

Eugen Tausch, MD, Christina Galler, Richard Schlenk, MD, Peter Hillmen, MBChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Jiri Mayer, MD, Sebastian Grosicki, MD, Panagiotis Panagiotidis, Daniel Mertens, PhD, Astrid McKeown, PhD, Ira Gupta, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1992.

https://doi.org/10.1182/blood.V124.21.1992.1992

Published: 2014

Journal Articles

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

Blood (2014) 124 (21): 1938.

https://doi.org/10.1182/blood.V124.21.1938.1938

Published: 2014

Journal Articles

NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors

Christine Wolf, Katharina Filarsky, Angela Garding, PhD, Rainer Claus, MD, Christopher C Oakes, PhD, Irina Idler, PhD, Christoph Plass, PhD, Peter Lichter, PhD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD, Daniel Mertens, PhD

Blood (2014) 124 (21): 1941.

https://doi.org/10.1182/blood.V124.21.1941.1941

Published: 2014

Journal Articles

ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia

Daniel Mertens, PhD, Danilo Allegra, PhD, Angela Garding, PhD, Hartmut Döhner, MD, Florian Kuchenbauer, MD, PhD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1252.

https://doi.org/10.1182/blood.V122.21.1252.1252

Published: 2013

Journal Articles

Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia

Christopher C Oakes, Ph.D, Rainer Claus, MD, Lei Gu, Yassen Assenov, Jennifer Hüllein, Manuela Zucknick, David Brocks, Olga Bogatyrova, Christopher R. Schmidt, Laura Rassenti, PhD, Thomas J. Kipps, MD, PhD, Daniel Mertens, PhD, Peter Lichter, PhD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, John C. Byrd, MD, Thorsten Zenz, MD, Christoph Plass, PhD

Blood (2013) 122 (21): 1626.

https://doi.org/10.1182/blood.V122.21.1626.1626

Published: 2013

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 2874.

https://doi.org/10.1182/blood.V120.21.2874.2874

Published: 2012

NARROW

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Towards Stratification of Lymphomas with Involvement of the Central Nervous System Using miRNA-Seq from Small Volumes of Cerebrospinal Fluid

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia

Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy

Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial

Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911)

Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial

NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors

ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia

Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only